• U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults • Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo® in the U.S. for travelers’ diarrhea • Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of...
RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia® is the first and only FDA approved rifabutin-based H. pylori therapy and is designed to address the high and growing bacterial resistance and...
In today for Talicia results (RHB-105) Technically above 6.5 - good All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management. This is not a recommendation to buy or sell.
Very critical month (November 2): Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 • Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019, subject to FDA approval, with...
Information is on the chart. Also check out our Youtube channel .
if it really completely? we can remove this ticker...
$RDHL like this for a pullback in low $11's for breakout to 200MA to $13